<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02340000</url>
  </required_header>
  <id_info>
    <org_study_id>3968</org_study_id>
    <nct_id>NCT02340000</nct_id>
  </id_info>
  <brief_title>Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate</brief_title>
  <official_title>Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to determine if high-dose amoxicillin/clavulanate is more effective than
      standard-dose amoxicillin/clavulanate in treating acute bacterial sinusitis in adults seen at
      a primary care office.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim was amended in February 2016--because of the unexpected unavailability of the
      original high-dose formulation of amoxicillin/clavulanate--to compare the effectiveness
      (versus standard dose) of extended-release (the original formulation) versus
      immediate-release amoxicillin/clavulanate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2014</start_date>
  <completion_date type="Actual">February 27, 2017</completion_date>
  <primary_completion_date type="Actual">February 27, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Improvement - Day 3 (Rating of &quot;a Lot Better&quot; or &quot;no Symptoms&quot;)</measure>
    <time_frame>end of 3 days of treatment</time_frame>
    <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-16 - Day 3</measure>
    <time_frame>day 0, end of 3 days of treatment</time_frame>
    <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 3 (values at day 0 minus values at day 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Improvement - Day 10</measure>
    <time_frame>end of 10th day</time_frame>
    <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SNOT-16 - Day 10</measure>
    <time_frame>day 0, end of 10th day</time_frame>
    <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 10 (values at day 0 minus values at day 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Colonization With Resistant Bacteria</measure>
    <time_frame>baseline</time_frame>
    <description>Clinicians performed anterior nasal cultures to look for colonization with penicillin-resistant pneumococci and other pathogens (stopped after participant #231 because of lack of funds).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to Take the Study Antibiotic in the Future</measure>
    <time_frame>end of 10th day</time_frame>
    <description>whether participants said they would NOT take the antibiotic again</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Sinusitis</condition>
  <arm_group>
    <arm_group_label>standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard dose amoxicillin/clavulanate</intervention_name>
    <description>amoxicillin/clavulanate 875/125 + placebo bid x 7 days</description>
    <arm_group_label>standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose amoxicillin/clavulanate</intervention_name>
    <description>Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days</description>
    <arm_group_label>high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult 18 or over

          2. Meets definition of acute sinusitis by Infectious Disease Society of America (2012)

          3. Clinician and participant chose to start antibiotic treatment

        Exclusion Criteria:

          1. Previously enrolled in the study

          2. Allergic or intolerant to amoxicillin, penicillin, or amoxicillin/clavulanate

          3. Specific medication concerns: lactating (since safety of clavulanate unknown); taking
             allopurinol (increased risk of rash); concurrent mononucleosis (increased risk of rash
             with amoxicillin); chronic kidney disease with glomerular filtration rate &lt; 30;
             significant hepatic impairment; history of antibiotic-associated colitis

          4. Cognitive impairment so that unable to give informed consent or give reliable
             assessment of improvement

          5. Need to use high-dose amoxicillin/clavulanate: treatment with amoxicllin or penicillin
             within the past month (risk of penicillin-resistant pneumococci), very ill patient
             (though not ill enough to send to hospital); immunocompromise

          6. Need to hospitalize the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albany Medical Center Internal Medicine and Pediatrics</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <zip>12110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, Pankey GA, Seleznick M, Volturo G, Wald ER, File TM Jr; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012 Apr;54(8):e72-e112. doi: 10.1093/cid/cir1043. Epub 2012 Mar 20.</citation>
    <PMID>22438350</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2015</study_first_posted>
  <results_first_submitted>July 16, 2017</results_first_submitted>
  <results_first_submitted_qc>August 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2017</results_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Paul Sorum, MD</investigator_full_name>
    <investigator_title>Professor of Internal Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>acute sinusitis</keyword>
  <keyword>amoxicillin/clavulanate</keyword>
  <keyword>adults</keyword>
  <keyword>outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Dose</title>
          <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
standard dose amoxicillin/clavulanate: amoxicillin/clavulanate 875/125 + placebo bid x 7 days</description>
        </group>
        <group group_id="P2">
          <title>High Dose</title>
          <description>Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
high dose amoxicillin/clavulanate: Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Time Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Time Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Dose</title>
          <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
standard dose amoxicillin/clavulanate: amoxicillin/clavulanate 875/125 + placebo bid x 7 days</description>
        </group>
        <group group_id="B2">
          <title>High Dose</title>
          <description>Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
high dose amoxicillin/clavulanate: Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="315"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="15.9"/>
                    <measurement group_id="B2" value="45.9" spread="14.8"/>
                    <measurement group_id="B3" value="46.9" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Active tobacco use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>COPD/asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>allergic rhinitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of sinusitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days of illness</title>
          <description>Clinician indicated the number of days the patient had been sick prior to the office visit.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.8" spread="8.8"/>
                    <measurement group_id="B2" value="14.3" spread="8.1"/>
                    <measurement group_id="B3" value="14.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 1</title>
          <description>Duration greater than or equal to 10 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 2</title>
          <description>Severe symptoms (most severe of the 3 categories)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinusitis category 3</title>
          <description>double sickening</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Day 0 SNOT-16 mean item score</title>
          <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="159"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.89" spread=".56"/>
                    <measurement group_id="B2" value="1.99" spread=".55"/>
                    <measurement group_id="B3" value="1.94" spread=".55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Improvement - Day 3 (Rating of &quot;a Lot Better&quot; or &quot;no Symptoms&quot;)</title>
        <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
        <time_frame>end of 3 days of treatment</time_frame>
        <population>The number of participants who gave ratings at the end of day 3 of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Time Period I</title>
            <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
standard dose amoxicillin/clavulanate: amoxicillin/clavulanate 875/125 + placebo bid x 7 days</description>
          </group>
          <group group_id="O2">
            <title>High Dose Time Period 1</title>
            <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Time Period 2</title>
            <description>Amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
          </group>
          <group group_id="O4">
            <title>High Dose Time Period 2</title>
            <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Improvement - Day 3 (Rating of &quot;a Lot Better&quot; or &quot;no Symptoms&quot;)</title>
          <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
          <population>The number of participants who gave ratings at the end of day 3 of treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SNOT-16 - Day 3</title>
        <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 3 (values at day 0 minus values at day 3).</description>
        <time_frame>day 0, end of 3 days of treatment</time_frame>
        <population>The number of participants who gave ratings at day 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Time Period I</title>
            <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
          </group>
          <group group_id="O2">
            <title>High Dose Time Period 1</title>
            <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Time Period 2</title>
            <description>amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
          </group>
          <group group_id="O4">
            <title>High Dose Time Period 2</title>
            <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
          </group>
        </group_list>
        <measure>
          <title>SNOT-16 - Day 3</title>
          <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 3 (values at day 0 minus values at day 3).</description>
          <population>The number of participants who gave ratings at day 3.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".75" spread=".63"/>
                    <measurement group_id="O2" value=".87" spread=".59"/>
                    <measurement group_id="O3" value=".91" spread=".63"/>
                    <measurement group_id="O4" value=".97" spread=".69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Improvement - Day 10</title>
        <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
        <time_frame>end of 10th day</time_frame>
        <population>The number of participants who gave a rating at day 10.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Time Period I</title>
            <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
          </group>
          <group group_id="O2">
            <title>High Dose Time Period 1</title>
            <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Time Period 2</title>
            <description>amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
          </group>
          <group group_id="O4">
            <title>High Dose Time Period 2</title>
            <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Improvement - Day 10</title>
          <description>rating of &quot;a lot better&quot; or &quot;no symptoms&quot;</description>
          <population>The number of participants who gave a rating at day 10.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SNOT-16 - Day 10</title>
        <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 10 (values at day 0 minus values at day 10).</description>
        <time_frame>day 0, end of 10th day</time_frame>
        <population>The number of participants who gave ratings at day 10.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Time Period I</title>
            <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
          </group>
          <group group_id="O2">
            <title>High Dose Time Period 1</title>
            <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Time Period 2</title>
            <description>amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
          </group>
          <group group_id="O4">
            <title>High Dose Time Period 2</title>
            <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
          </group>
        </group_list>
        <measure>
          <title>SNOT-16 - Day 10</title>
          <description>Ratings on a scale from 0=none to 3=severe of 16 sinusitis-related symptoms. Total score can range from 0 to 48 (with 48 the most severe possible) of the 16 symptoms.
The outcome measure was the mean difference in the ratings of each of the 16 symptoms between day 0 and day 10 (values at day 0 minus values at day 10).</description>
          <population>The number of participants who gave ratings at day 10.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread=".71"/>
                    <measurement group_id="O2" value="1.48" spread=".64"/>
                    <measurement group_id="O3" value="1.37" spread=".67"/>
                    <measurement group_id="O4" value="1.40" spread=".73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Colonization With Resistant Bacteria</title>
        <description>Clinicians performed anterior nasal cultures to look for colonization with penicillin-resistant pneumococci and other pathogens (stopped after participant #231 because of lack of funds).</description>
        <time_frame>baseline</time_frame>
        <population>All 231 participants were analyzed together regardless of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall</title>
            <description>First 231 participants</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Colonization With Resistant Bacteria</title>
          <description>Clinicians performed anterior nasal cultures to look for colonization with penicillin-resistant pneumococci and other pathogens (stopped after participant #231 because of lack of funds).</description>
          <population>All 231 participants were analyzed together regardless of treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No growth or normal flora</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methicillin-sensitive Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemophilus influenzae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Streptococcus pneumoniae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moxarella catarrhalis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staphylococcus epidermidis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methicillin-resistant Staphylococcus aureus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Willingness to Take the Study Antibiotic in the Future</title>
        <description>whether participants said they would NOT take the antibiotic again</description>
        <time_frame>end of 10th day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Dose Time Period I</title>
            <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
          </group>
          <group group_id="O2">
            <title>High Dose Time Period 1</title>
            <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Standard Dose Time Period 2</title>
            <description>amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
          </group>
          <group group_id="O4">
            <title>High Dose Time Period 2</title>
            <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
          </group>
        </group_list>
        <measure>
          <title>Willingness to Take the Study Antibiotic in the Future</title>
          <description>whether participants said they would NOT take the antibiotic again</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 days</time_frame>
      <desc>The number of participants reporting adverse effects was less than the number initially at risk because some patients withdrew before starting treatment or were lost to follow-up for the study. Since they were all patients in our practice, however, we knew--outside of the study---that none of them suffered death or other serious adverse effects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Standard Dose Time Period I</title>
          <description>amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days</description>
        </group>
        <group group_id="E2">
          <title>High Dose Time Period 1</title>
          <description>extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets twice a day for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Standard Dose Time Period 2</title>
          <description>amoxicillin/clavulnate 875/125 plus placebo bid x 7 days</description>
        </group>
        <group group_id="E4">
          <title>High Dose Time Period 2</title>
          <description>immediate-release amoxicillin/clavunate 872/125 plus amoxicillin 875</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <description>diarrhea at day 3</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="87"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="80"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="62"/>
                <counts group_id="E4" events="27" subjects_affected="27" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginitis</sub_title>
                <description>vaginal itching or discharge at day 3</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Initial formulation of high-dose amox/clav (extended release) became unavailable, so had to switch after participant #180 to immediate-release.
The medical students and residents had trouble reaching some participants for follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Sorum, MD</name_or_title>
      <organization>Albany Medical College</organization>
      <phone>5182627500</phone>
      <email>sorump@mail.amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

